OA1: from molecular bases to gene delivery

OA1:从分子基础到基因传递

基本信息

  • 批准号:
    6948462
  • 负责人:
  • 金额:
    $ 40.03万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-30 至 2008-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ocular albinism type 1 is characterized by impaired visual acuity, nystagmus, photophobia, strabismus and loss of stereoscopic vision. It is inherited as an X chromosome-linked trait. Similarly to other types of albinism, it is associated with misrouting of the optic tracts during development. The histopathological hallmark of the disease is the presence of macromelanosomes in both skin melanocytes and retinal pigment epithelium (RPE). Following identification of the OA1 gene, several loss-of-function mutations were identified in patients. However, these account for approximately 70% of the cases studied, the remaining mutations being so far undetected. The OA1 protein product shares sequence similarity with G-protein coupled receptors and binds G proteins. Unlike most members of this protein family, OA1 is intracellular, being located on the melanosomal membrane. Both the macromelanosomal phenotype and the subcellular localization of the OA1 protein suggest a defect in melanosome biogenesis in ocular albinism. However, the precise role of OA1 in this fundamental process is still unknown. An important model system to study OA1 function and disease pathogenesis is the OA1 knock-out mouse which recapitulates the human disease phenotype. The goals of this project are to: 1) identify the full spectrum of mutations causing the disease, 2) study the requirement of OA1 during visual system development and maintenance, 3) discover the pathogenetic steps leading from mutations of the OA1 gene to disease phenotype, 4) characterize the functional interaction of OA1 with other genes involved in albinism to understand their role in melanosome biogenesis, 5) develop both pre- and post- natal OA1 gene delivery approaches to the RPE of animal models, aiming at phenotype prevention and rescue, respectively. These studies will advance our understanding of OA1 function in pigmentation, RPE function, melanosome biogenesis, and optic nerve development. In addition, they will lead to a deeper understanding of the pathogenesis of ocular albinism type 1 as well as of other types of albinism. Finally, the gene delivery approaches developed may represent important tools for future treatment of eye diseases involving RPE.
描述(由申请人提供):1型眼白化病的特征为视力受损、眼球震颤、斜视、斜视和立体视觉丧失。它是作为X染色体连锁性状遗传的。与其他类型的白化病相似,它与发育过程中视神经束的错误路由有关。该疾病的组织病理学标志是皮肤黑素细胞和视网膜色素上皮(RPE)中存在大黑素体。在OA1基因的鉴定之后,在患者中鉴定了几种功能丧失突变。然而,这些占研究病例的约70%,其余突变迄今未被检测到。OA1蛋白产物与G蛋白偶联受体具有序列相似性并结合G蛋白。与该蛋白家族的大多数成员不同,OA1是细胞内的,位于黑素体膜上。大黑素体表型和OA1蛋白的亚细胞定位都表明眼白化病中黑素体生物发生的缺陷。然而,OA1在这一基本过程中的确切作用仍然未知。研究OA1功能和疾病发病机制的重要模型系统是OA1敲除小鼠,其重现了人类疾病表型。该项目的目标是:1)鉴定引起该疾病的突变的全谱,2)研究视觉系统发育和维持过程中OA1的需求,3)发现从OA1基因突变到疾病表型的发病步骤,4)表征OA1与参与白化病的其他基因的功能相互作用以理解它们在黑素体生物发生中的作用,5)开发针对动物模型的RPE的产前和纳塔尔OA1基因递送方法,分别旨在表型预防和拯救。这些研究将促进我们对OA1在色素沉着、RPE功能、黑素体生物发生和视神经发育中的功能的理解。此外,他们将导致更深入地了解眼白化病1型以及其他类型的白化病的发病机制。最后,开发的基因递送方法可能是未来治疗涉及RPE的眼部疾病的重要工具。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREA BALLABIO其他文献

ANDREA BALLABIO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREA BALLABIO', 18)}}的其他基金

Dissecting and targeting lysosomal signaling in kidney tumorigenesis
解析和靶向肾肿瘤发生中的溶酶体信号传导
  • 批准号:
    10367500
  • 财政年份:
    2022
  • 资助金额:
    $ 40.03万
  • 项目类别:
Dissecting and targeting lysosomal signaling in kidney tumorigenesis
解析和靶向肾肿瘤发生中的溶酶体信号传导
  • 批准号:
    10594980
  • 财政年份:
    2022
  • 资助金额:
    $ 40.03万
  • 项目类别:
MODULATION OF CELLULAR CLEARANCE TO TREAT HUMAN DISEASE
调节细胞清除率来治疗人类疾病
  • 批准号:
    9069100
  • 财政年份:
    2012
  • 资助金额:
    $ 40.03万
  • 项目类别:
MODULATION OF CELLULAR CLEARANCE TO TREAT HUMAN DISEASE
调节细胞清除率来治疗人类疾病
  • 批准号:
    8660354
  • 财政年份:
    2012
  • 资助金额:
    $ 40.03万
  • 项目类别:
Modulation of Cellular Clearance to Treat Human Disease
调节细胞清除来治疗人类疾病
  • 批准号:
    10021456
  • 财政年份:
    2012
  • 资助金额:
    $ 40.03万
  • 项目类别:
MODULATION OF CELLULAR CLEARANCE TO TREAT HUMAN DISEASE
调节细胞清除率来治疗人类疾病
  • 批准号:
    8536404
  • 财政年份:
    2012
  • 资助金额:
    $ 40.03万
  • 项目类别:
MODULATION OF CELLULAR CLEARANCE TO TREAT HUMAN DISEASE
调节细胞清除率来治疗人类疾病
  • 批准号:
    8437979
  • 财政年份:
    2012
  • 资助金额:
    $ 40.03万
  • 项目类别:
Modulation of Cellular Clearance to Treat Human Disease
调节细胞清除来治疗人类疾病
  • 批准号:
    9379350
  • 财政年份:
    2012
  • 资助金额:
    $ 40.03万
  • 项目类别:
Ocular Albinism type 1: from molecular bases to gene delivery
1 型眼白化病:从分子基础到基因传递
  • 批准号:
    7287289
  • 财政年份:
    2003
  • 资助金额:
    $ 40.03万
  • 项目类别:
OA1: from molecular bases to gene delivery
OA1:从分子基础到基因传递
  • 批准号:
    7121108
  • 财政年份:
    2003
  • 资助金额:
    $ 40.03万
  • 项目类别:

相似海外基金

GENOMICE (Game Exploring Nuances in Offspring to Master Interactions of Chromosome Expression)
GENOMICE(探索后代细微差别以掌握染色体表达相互作用的游戏)
  • 批准号:
    10760456
  • 财政年份:
    2023
  • 资助金额:
    $ 40.03万
  • 项目类别:
Molecular Mechanisms Underlying Endothelial Weibel-Palade Body Biogenesis and Exocytosis
内皮 Weibel-Palade 体生物发生和胞吐作用的分子机制
  • 批准号:
    10796566
  • 财政年份:
    2023
  • 资助金额:
    $ 40.03万
  • 项目类别:
Development and Validation of Photothermal Optical Coherence Tomography for Retinal Imaging
用于视网膜成像的光热光学相干断层扫描的开发和验证
  • 批准号:
    10550200
  • 财政年份:
    2022
  • 资助金额:
    $ 40.03万
  • 项目类别:
Retinal Contributions to Vision Loss in Albinism
视网膜对白化病视力丧失的影响
  • 批准号:
    10652487
  • 财政年份:
    2022
  • 资助金额:
    $ 40.03万
  • 项目类别:
A Human Rights and Equity-Oriented Response to the Birth Stories of Families Impacted by Albinism in Sub-Saharan Africa: Intersectoral Partnerships for Enhanced Health Professions' Education
对撒哈拉以南非洲地区受白化病影响的家庭的出生故事采取以人权和公平为导向的应对措施:加强卫生专业教育的部门间伙伴关系
  • 批准号:
    463437
  • 财政年份:
    2022
  • 资助金额:
    $ 40.03万
  • 项目类别:
    Operating Grants
Development and Validation of Photothermal Optical Coherence Tomography for Retinal Imaging
用于视网膜成像的光热光学相干断层扫描的开发和验证
  • 批准号:
    10380391
  • 财政年份:
    2022
  • 资助金额:
    $ 40.03万
  • 项目类别:
Retinal Contributions to Vision Loss in Albinism
视网膜对白化病视力丧失的影响
  • 批准号:
    10464283
  • 财政年份:
    2022
  • 资助金额:
    $ 40.03万
  • 项目类别:
Molecular Determinants of Pigmentation (MDoP)
色素沉着的分子决定因素 (MDoP)
  • 批准号:
    10451535
  • 财政年份:
    2021
  • 资助金额:
    $ 40.03万
  • 项目类别:
Mechanisms of cAMP-dependent regulation of melanosome pH
cAMP 依赖性黑素体 pH 调节机制
  • 批准号:
    10596538
  • 财政年份:
    2021
  • 资助金额:
    $ 40.03万
  • 项目类别:
Molecular Determinants of Pigmentation (MDoP)
色素沉着的分子决定因素 (MDoP)
  • 批准号:
    10665677
  • 财政年份:
    2021
  • 资助金额:
    $ 40.03万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了